Safety of NSAIDs in patients diagnosed with COVID-19

Main Article Content

Melissa Daniela Cedillo Rivera
Rosa Elizabeth Pichazaca Mayancela
Maritza del Rosario Martínez León

Abstract

Introduction: NSAIDs are defined as non-steroidal anti-inflammatory drugs, which represent a heterogeneous chemical pharmacological group. It is used in the treatment of COVID-19 in patients with mild or moderate symptoms. Objective:  to analyzer the use of non-steroidal anti-inflammatory drugs in the treatment of clinical manifestations presented in patients with SARS-CoV-2, in addition to evidencing which are the most frequent NSAIDs, in the same way that doses can generate damage and if these can cause morbidities. Methodology: a bibliographic compilation was conducted to arrange data related to patients who consume NSAIDs and the presumed decline of their symptoms, fluid retention, kidney problems, heart problems after the consumption of these drugs. Resulted: the ibuprofen (58.6%) and aceclofenac (2.7%) should be identified as the most used oral options for the COVID-19 palliative procedure. The standardized dose used in the treatment of patients with COVID-19 is 400 mg every 6 to 8 hours. Conclusions: NSAIDs are commonly used in COVID-19 patients, but certain hospitals recommend that first-line providers perform an evaluation on use. It is important to know the symptoms that the patient is experiencing to avoid the use of NSAIDs. Specific area of study: Pharmacology.

Downloads

Download data is not yet available.

Article Details

How to Cite
Cedillo Rivera, M. D., Pichazaca Mayancela, R. E., & Martínez León, M. del R. (2023). Safety of NSAIDs in patients diagnosed with COVID-19. Anatomía Digital, 6(2), 83-93. https://doi.org/10.33262/anatomiadigital.v6i2.2552
Section
Artículos